Know Cancer

or
forgot password

A Phase I, Multi-Center, Open-label Study of IMGN529 Administered Intraveneously in Adult Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma


Phase 1
18 Years
N/A
Open (Enrolling)
Both
Lymphoma, Non-Hodgkin

Thank you

Trial Information

A Phase I, Multi-Center, Open-label Study of IMGN529 Administered Intraveneously in Adult Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma


Inclusion Criteria:



- Relapsed or refractory NHL including tumor types: Follicular lymphoma (FL), marginal
zone lymphoma (MZL)/mucosa-associated lymphoid tissue (MALT), diffuse large B-cell
lymphoma (DLBCL), mantle cell lymphoma (MCL).

- Adequate organ function

- ECOG ≤ 2

- Recovered or stabilized from prior treatments.

Exclusion Criteria:

- Allogeneic stem cell transplantation

- Pregnant or lactating females

- Known central nervous system, meningeal or epidural disease including brain
metastases

Type of Study:

Interventional

Study Design:

Intervention Model: Single Group Assignment, Masking: Open Label

Outcome Measure:

Occurrence of dose limiting toxicities

Authority:

United States: Food and Drug Administration

Study ID:

IMGN0301

NCT ID:

NCT01534715

Start Date:

January 2012

Completion Date:

Related Keywords:

  • Lymphoma, Non-Hodgkin
  • Lymphoma
  • Lymphoma, Non-Hodgkin

Name

Location

Dana Farber Cancer InstituteBoston, Massachusetts  02115
Ohio State UniversityColumbus, Ohio  43210
Sarah Cannon Research InstituteNashville, Tennessee  37203